Danaher
DANAHER CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$24.6B
Operating marginCalculated
19.1%
Net assets to total assetsCalculated
62.9%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
19.1%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.2%
Capital efficiency
★★☆☆☆position among all companies
6.9%
Revenue and profit
Performance, financial position and capital allocation
Danaher
Recent performance trends
Danaher
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$24.8 billion | US$26.6 billion | US$23.9 billion | US$23.9 billion | US$24.6 billion |
| Operating income | US$6.4 billion | US$7.5 billion | US$5.2 billion | US$4.9 billion | US$4.7 billion |
| Net income | US$6.4 billion | US$7.2 billion | US$4.8 billion | US$3.9 billion | US$3.6 billion |
| Total assets | US$83.2 billion | US$84.3 billion | US$84.5 billion | US$77.5 billion | US$83.5 billion |
| Shareholders' equity | US$45.2 billion | US$50.1 billion | US$53.5 billion | US$49.5 billion | US$52.5 billion |
| Net cash provided by (used in) operating activities | US$8.4 billion | US$8.5 billion | US$7.2 billion | US$6.7 billion | US$6.4 billion |
| Net cash provided by (used in) investing activities | US$-13.0 billion | US$-2.2 billion | US$-7.1 billion | US$-2.0 billion | US$-1.2 billion |
| Net cash provided by (used in) financing activities | US$1.3 billion | US$-2.6 billion | US$-0.3 billion | US$-8.4 billion | US$-3.0 billion |
| Cash and cash equivalents | US$2.6 billion | US$6.0 billion | US$5.9 billion | US$2.1 billion | US$4.6 billion |
Revenue scale in the same industry
Danaher
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 1 companies
- 5 StrykerFY Dec 2025 US$25.1B
- 6 3MFY Dec 2025 US$24.9B
- 7 DanaherThis companyFY Dec 2025 US$24.6B
- 8 BECTON, Dickinson ANDFY Sep 2025 US$21.8B
- 9 L3HARRIS TechnologiesFY Jan 2025 US$21.3B
- … 34 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.2 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$4.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$6.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.8 billion | Consolidated | Disclosed |
| Dividends paid | US$0.9 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$52.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$7.00 million | Consolidated | Disclosed |
| Net assets | US$52.5 billion | Consolidated | Disclosed |
| Net sales | US$24.6 billion | Consolidated | Disclosed |
| Operating income | US$4.7 billion | Consolidated | Disclosed |
| Net income | US$3.6 billion | Consolidated | Disclosed |
| Total assets | US$83.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$3.1 billion | Consolidated | Disclosed |
| Operating margin | 19.1% | Consolidated | Calculated |
| Net assets to total assets | 62.9% | Consolidated | Calculated |
| Net margin | 14.7% | Consolidated | Calculated |
| Return on equity | 6.9% | Consolidated | Calculated |